FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers[1][2].
FAPI-46 (1-24 h) robustly binds to human FAP in human FAP-expressing HT-1080 cells[1].
FAPI-46 (i.v.) shows improved ratios of tumor to liver, kidney, and brain uptake, resulting in an enhanced image contrast for PET imaging[1].
[1]. Loktev A, et, al. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. J Nucl Med. 2019 Oct;60(10):1421-1429.
[2]. Moon ES, et, al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA 5m chelators. EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19.